Biogen Idec Inc (NASDAQ:BIIB): A Biotech Pioneer With A Stellar Future WallStreetPR Daclizumab for RRMS is another drug in the pipeline. Tysabri is being developed for the treatment of SPMS. If this pans out, Tysabri sales might reach a peak of $5.2 billion. More drugs under development include anti-LINGO for MS, BIB037 and BAN2401 ... |
